Other Publications (1)
Articles by Xiaoqiong Wu in JoVE
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity Yanlan Wang1,2, Jiayu Liu1,2, Haitao Pan1,2, Jieyu Xing1,2, Xiaoqiong Wu1,2, Qing Li1,2, Zhong Wang1,2 1School of Pharmaceutical Sciences, Sun Yat-Sen University, 2Center for Cellular & Structural Biology, Sun Yat-Sen University Here, we present a protocol to produce a bispecific antibody GPC3-S-Fab in Escherichia coli. The purified GPC3-S-Fab has potent cytotoxicity against GPC3 positive liver cancer cells.
Other articles by Xiaoqiong Wu on PubMed
A Single Domain-Based Anti-Her2 Antibody Has Potent Antitumor Activities Translational Oncology. | Pubmed ID: 29455083 Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer patients. However, relapse or resistance is frequent with the current therapies. To generate a new treatment avenue against Her2, we immunized and selected a specific anti-Her2 single domain antibody C3 for further studies. The C3-Fc antibody drove antibody-dependent cell-mediated cytotoxicity against Her2-positive tumor cells in vitro and resulted in potent antitumor growth in vivo. These data suggest that the C3-Fc antibody may provide an alternative avenue for Her2-positive cancer therapy.